A study to measure markers in the breath of patients with Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary DiseaseRespiratory - Chronic obstructive pulmonary disease
- Registration Number
- ACTRN12614000617662
- Lead Sponsor
- ung Institute of Western Australia
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 200
The people eligible for the study are patients with 1)COPD. based on the criteria described below. 2) Healthy controls with no COPD and within the same age range as subjects with COPD.
1.GOLD Criteria for severity of COPD
a.Mild – FEV1/FVC< 70%, FEV1< 80%
b.Moderate – FEV1/FVC< 70%, FEV1 50-80%
2.COPD chronic bronchitis or Emphysema
3.Age – 50-70 years
4.males and females
1.Present smokers
2.Severe CCF
3.Liver, renal failure
4.Diabetes
5.On immunosuppressive drugs
6.Auto-immune conditions such RA
7.Vascular disease – Scleroderma , SLE
8.Any history of asthma
9.Exacerbations in the last 6 weeks
10.Women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding
11.Known sensitivity to study drug(s) or class of study drug(s)
12.Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of drug on volatile organic compounds. The drug will be given to the subject for 10 days. At the end of this period the patient will blow into a tube that would collect the exhaled breath. That tube will be sent for analysis to determine the number and concentration of organic compounds.[10 days]
- Secondary Outcome Measures
Name Time Method Improvement in lung function including FEV1. FEV1 is meaured by spirometry[10 days]